Anti-Parkinson botanical Mucuna pruriens prevents levodopa induced plasmid and genomic DNA damage

Phytotherapy Research

Volumn 21, Issue 12, 2007, Pages 1124-1126

  Tharakan, Binu ^a   Dhanasekaran, Muralikrishnan ^b   Mize Berge, Janna ^a   Manyam, Bala V ^a,c,d  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b AUBURN UNIVERSITY   (United States)

^c TEXAS A M COLLEGE OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Copper; DNA; Levodopa; Mucuna pruriens; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; CHELATING AGENT; COPPER; DIVALENT CATION; GENOMIC DNA; HERBACEOUS AGENT; LEVODOPA; PLASMID DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHELATION; CONTROLLED STUDY; COTYLEDON; DNA DAMAGE; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG MECHANISM; NONHUMAN; PARKINSON DISEASE; POWDER; PROTECTION; VELVET BEAN;

ANIMALS; ANTIPARKINSON AGENTS; CATTLE; COTYLEDON; DNA DAMAGE; LEVODOPA; MUCUNA; PLANT EXTRACTS; PLASMIDS;

ANIMALIA; MUCUNA PRURIENS;

EID: 37849051912     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2219     Document Type: Article

References (19)

1. Asad SF, Singh S, Ahmad A, Hadi SM. 2000. Inhibition of L-DOPA-Cu(II)-mediated DNA cleavage by bilirubin. Toxicol In Vitro 14: 401-404.
2. Dexter DT, Carter CJ, Wells FR et al. 1989. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389.
3. HP-200 in Parkinson's Disease Study Group (Manyam BV, Principal Investigator and Senior Author). 1995. HP-200: An 'alternative medicine' treatment for Parkinson's disease. J Alternat Comp Med 1: 249-255.
4. Husain S, Hadi SM. 1995. Strand scission in DNA induced by L-DOPA in the presence of Cu(II). FEBS Lett 364: 75-78.
5. Hussain G, Manyam BV. 1997. Mucuna pruriens proves more effective than L-DOPA in Parkinson's disease animal model. Phytother Res 11: 419-423.
6. Katzenschlager R, Evans A, Manson A et al. 2004. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 75: 1672-1677.
7. Liu WG, Chen Y, Li B, Lu GQ, Chen SD. 2004. Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells. Neurochem Res 29: 2207-2214.
8. Manyam BV. 1990. Paralysis agitans and levodopa in 'Ayurveda', ancient Indian medical treatise. Mov Disord 5: 47-48.
9. Manyam BV, Parikh KM. 2003. Antiparkinsonian activity of Mucuna pruriens seeds. Ann Neurosci 9: 40-46.
10. Manyam BV, Dhanasekaran M, Hare T. 2004a. Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters. Phytother Res 18: 97-101.
11. Manyam BV, Dhanasekaran M, Hare T. 2004b. Neuroprotective effects of antiparkinson drug Mucuna pruriens. Phytother Res 18: 706-712.
12. Nagashayana N, Sankarankutty P, Nampoothiri MR, Mohan PK, Mohanakumar KP. 2000. Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease. J Neurol Sci 176: 124-127.
13. Singh S, Farhan AS, Hadi SM. 1998. Uric acid inhibits L-DOPA-CU(II) mediated DNA cleavage. Neurosci Lett 258: 69-72.
14. Snyder RD, Friedman MB. 1998. Enhancement of cytotoxicity and clastogenicity of l-DOPA and dopamine by manganese and copper. Mutat Res 405: 1-8.
15. Spencer JP, Jenner A, Aruoma OI et al. 1994. Intense oxidative DNA damage promoted by L-DOPA and its metabolites. Implications for neurodegenerative disease. FEBS Lett 353: 246-250.
16. Spencer JP, Whiteman M, Jenner P, Halliwell B. 2002. 5-s-Cysteinyl- conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J Neurochem 81: 122-129.
17. Subramanian T, Tidwell NE, Garg S et al. 2002. Mucuna pruriens seed extract ameliorates parkinsonian disability in hemiparkinsonian (HP) monkeys. Society for Neuroscience, Washington, DC. Program No. 326.9. Society of Neuroscience, Washington DC.
18. Tanaka K, Ogawa N. 2005. Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice. Neurosci Res 51: 9-13.
19. Tanaka M, Yoshida T, Okamoto K, Hirai S. 1999. Dopamine and DOPA cause release of iron from ferritin and lipid peroxidation of liposomes. Neuroreport 10: 1883-1887.